|
Dexcom G8 Promises Smaller Size and Adaptive Accuracy
|
Written by: J. Smith |
Hits: 62
|
|
New ACHIEVE-4 Data May Help Address FDA Safety Questions on Lilly’s Foundayo
|
Written by: J. Smith |
Hits: 118
|
|
Novo Nordisk Expands AI Strategy Through New OpenAI Partnership
|
Written by: J. Smith |
Hits: 129
|
|
Lilly’s Foundayo Approval Brings a More Flexible GLP-1 Pill to Weight Loss Care
|
Written by: J. Smith |
Hits: 110
|
|
Novo Nordisk Reports Promising Phase 2 Data for UBT251 in Type 2 Diabetes
|
Written by: J. Smith |
Hits: 125
|
|
Novo Nordisk Expands DTC Push With New Wegovy Subscription Program
|
Written by: J. Smith |
Hits: 120
|
|
FDA Approves Awiqli as First Once-Weekly Basal Insulin for Type 2 Diabetes
|
Written by: J. Smith |
Hits: 131
|
|
Retatrutide’s First Phase 3 Diabetes Results Draw Attention for More Than Strong Numbers
|
Written by: J. Smith |
Hits: 184
|
|
FDA Approves Wegovy HD, Adding a Higher-Dose Semaglutide Option for Obesity
|
Written by: J. Smith |
Hits: 161
|
|
Zealand Pharma Reports Phase 2 Results for Petrelintide
|
Written by: J. Smith |
Hits: 184
|
